0001179110-20-007717.txt : 20200623 0001179110-20-007717.hdr.sgml : 20200623 20200623161357 ACCESSION NUMBER: 0001179110-20-007717 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200619 FILED AS OF DATE: 20200623 DATE AS OF CHANGE: 20200623 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lydon Nicholas CENTRAL INDEX KEY: 0001639935 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37359 FILM NUMBER: 20982044 MAIL ADDRESS: STREET 1: BLUEPRINT MEDICINES CORP. STREET 2: 215 FIRST STREET, SUITE 340/350 CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Blueprint Medicines Corp CENTRAL INDEX KEY: 0001597264 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 45 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-374-7580 MAIL ADDRESS: STREET 1: 45 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 edgar.xml FORM 4 - X0306 4 2020-06-19 0 0001597264 Blueprint Medicines Corp BPMC 0001639935 Lydon Nicholas C/O BLUEPRINT MEDICINES CORPORATION 45 SIDNEY STREET CAMBRIDGE MA 02139 1 0 0 0 Common Stock 2020-06-19 4 M 0 1312 A 89039 D Common Stock 2020-06-22 4 S 0 13017 80.29 D 76022 D Restricted Stock Units 2020-06-19 4 M 0 1312 0 D Common Stock 1312 0 D Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Effected pursuant to a trading plan adopted on February 27, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.96 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. On June 19, 2019, the reporting person was granted 1,312 restricted stock units. These restricted stock units are fully vested. /s/ Christopher Frankenfield, Attorney-in-Fact 2020-06-23